Dermatology Specialties Limited Partnership

• Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

  Phase 2/3, Completed, 107 people, 1 Feb 2019

Sources: clinicaltrials.gov